Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 9/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 9/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72667 | 1.00 | ITGB1 (0.49) | ITGB1ITGA4MAPTKMT2APOLB | |
| SCHEMBL71060 | 0.96 | ITGB1 (0.54) | ITGB1ITGA4MAPTKMT2APOLB | |
| SCHEMBL71061 | 0.96 | ITGB1 (0.54) | ITGB1ITGA4MAPTKMT2APOLB | |
| SCHEMBL70581 | 0.93 | ITGB1 (0.56) | ITGB1ITGA4KMT2AKDM1A | |
| SCHEMBL70580 | 0.93 | ITGB1 (0.56) | ITGB1ITGA4KMT2AKDM1A | |
| SCHEMBL71428 | 0.93 | ITGB1 (0.50) | ITGB1ITGA4MAPTKMT2APOLB | |
| SCHEMBL71429 | 0.93 | ITGB1 (0.50) | ITGB1ITGA4MAPTKMT2APOLB | |
| SCHEMBL72835 | 0.93 | ITGB1 (0.53) | ITGB1ITGA4MAPTKMT2APOLB | |
| SCHEMBL72836 | 0.93 | ITGB1 (0.53) | ITGB1ITGA4MAPTKMT2APOLB | |
| SCHEMBL71809 | 0.92 | ITGB1 (0.49) | ITGB1ITGA4MAPTKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961750-B1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO CO LTD (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | ITGB1 13/4885ITGA4 3/4885MAPT 4773/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | ITGB1 22/4885ITGA4 3/4885MAPT 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.